-Treatment with VX-770 resulted in improvements in lung function and markers of disease- -There were no discontinuations of treatment due to adverse events- -Late-stage Phase 3 clinical trials for VX-770 ongoing- CAMBRIDGE, Mass., Nov 17, 2010 (BUSINESS WIRE)-- In a study published in this week's
-New treatment arm to evaluate all oral, triple combination regimen of telaprevir, VX-222, and ribavirin- CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2
<i>-75% of people treated in the Phase 3 ADVANCE study achieved a viral
cure with telaprevir; majority of people treated for a total of 24 weeks-</i>
<br />
<i>-62% of African Americans/Blacks in the ADVANCE study achieved a
viral cure with telaprevir-</i>
<br />
<i>-Low discontinuation rates of all drugs due to adverse events-</i>
<br />
<i>-Hepatitis C:</i> <i>New Drug Application submission for telaprevir
on track for fourth quarter 2010-</i>
<br />
<i>-Cystic Fibrosis:</i> <i>Phase 3 registration program ongoing for
VX-770-</i>
<br />
<i>-Pipeline:</i> <i>Ongoing proof-of-concept clinical trials in
hepatitis C, cystic fibrosis, epilepsy and rheumatoid arthritis-</i>
<br />
<i>-Financial:</i> <i>Company ends third quarter with a cash position of
$1.2 billion-</i>
<br />
<i>- First Phase 3 study to evaluate twice-daily (BID) dosing of a
protease inhibitor for hepatitis C -</i>
<br />
<i>- All patients will receive telaprevir-based combination therapy -</i>
<br />
<i><b>-Primary endpoints of safety, tolerability and effect on CFTR
function as measured by sweat chloride-</b></i>
<br />
<i><b>-Phase 2a proof of mechanism clinical trial to enroll people with
the most common mutation of cystic fibrosis, known as F508del-</b></i>
<br />
CAMBRIDGE, Mass., Sep 24, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate
CAMBRIDGE, Mass., Sep 23, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015.
CAMBRIDGE, Mass., Sep 22, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that intends to offer, subject to market and other conditions, $375.0 million aggregate principal amount of convertible senior subordinated notes due 2015 in an underwritten public
<i>-17% of people achieved SVR with pegylated-interferon and ribavirin
alone in the control arm-</i>
<br />
<i>-Safety and tolerability results were consistent with prior Phase 3
studies-</i>
<br />
<i>-Completion of rolling New Drug Application submission on track for
the fourth quarter 2010-</i>
<br />
<i>-Viral cure rates of 92% and 88% with 24 and 48-week regimens,
respectively, in people who met certain response criteria-</i>
<br />
<i>-Safety and tolerability results were similar to those seen in the
Phase 3 ADVANCE study</i>-
<br />
<i>-Hepatitis C: Rolling submission of New Drug Application underway;
data from second pivotal Phase 3 trial - REALIZE - expected in the third
quarter of 2010-</i>
<br />
<i>-Cystic Fibrosis: Phase 3 registration program for VX-770 fully
enrolled; data expected in first half of 2011-</i>
<br />
<i>-Financial: Vertex ends second quarter with cash position of
approximately $980 million-</i>
<br />
CAMBRIDGE, Mass., Jul 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Wayne J. Riley, M.D., M.B.A., joined its board of directors as an independent director. The addition of Dr. Riley brings the number of Vertex board members to 10. Dr.
<i><b>-Majority of patients treated with telaprevir received a 24-week
regimen-</b></i>
<br />
<i><b>-6.9% and 7.7% treatment discontinuation rates due to adverse
events in 12- and 8-week telaprevir-based treatment arms -- lower than
previous telaprevir trials-</b></i>
<br />
<i><b>-First Phase 3 trial results for a direct acting antiviral therapy
in hepatitis C-</b></i>
<br />
CAMBRIDGE, Mass., May 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2010 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Dr. Joshua Boger, Dr. Charles A. Sanders and Elaine S.
<i>-HCV: Rolling submission of New Drug Application for telaprevir
expected to begin in summer of 2010; first Phase 3 SVR data expected in
second quarter 2010 from ADVANCE trial-</i>
<br />
<i>-CF: STRIVE, ENVISION and DISCOVER trials dosing patients as part of
Phase 3 registration program for VX-770; data expected in first half of
2011-</i>
<br />
<i>-Pipeline: Multiple ongoing or planned proof-of-concept clinical
trials with compounds for rheumatoid arthritis and epilepsy and with
novel combination regimens for HCV and CF-</i>
<br />
<i>-Financial: Vertex ends first quarter with cash position of
approximately $1.1 billion-</i>
<br />
<i>-VX-222 was well-tolerated across all four dose groups through three
days of dosing, with all adverse events being mild to moderate in
severity-</i>
<br />
<i>-Greater than 3 log</i><sub><i>10 </i></sub><i>reduction in HCV RNA
observed across all four VX-222 dose groups-</i>
<br />
<i>-Results support previously announced Phase 2 proof-of-concept
clinical trial evaluating VX-222 in combination with Vertex's lead HCV
protease inhibitor telaprevir-</i>
<br />
<i>-56% of prior treatment null responder patients achieved SVR with a
48-week telaprevir-based regimen-</i>
<br />
<i>-97% of prior treatment relapsers and 55% of prior treatment partial
responders achieved SVR with 24-week or 48-week telaprevir-based
regimens-</i>
<br />
<i><b>-51% and 53% SVR rates when telaprevir was dosed in combination
with pegylated-interferon and ribavirin in treatment-failure patients,
compared to 14% SVR rate with pegylated-interferon and ribavirin alone-</b></i>
<br />
<i><b>-Telaprevir Phase 3 SVR data expected in second quarter 2010 for
treatment-naïve patients and third quarter 2010 for treatment-failure
patients-</b></i>
<br />
<i><b>-New Drug Application submission planned for second half of 2010
in treatment-naïve and treatment-failure HCV patients-</b></i>
<br />
CAMBRIDGE, Mass., Mar 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45 th
<i>-Trial will evaluate safety and SVR rates with multiple 12-week
response-guided regimens of telaprevir/VX-222-based combination therapy,
including two-drug regimens of telaprevir and VX-222-</i>
<br />
<i>-Interim clinical data expected in the second half of 2010-</i>
<br />
<i>-Multiple clinical trial sites in the U.S. to enroll patients-</i>
<br />
CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 19, 2010 it will redeem the outstanding $32.1 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2013, in accordance with the terms of the
<i>-HCV: New Drug Application planned for telaprevir in second half of
2010; increasing investment in commercialization and launch preparedness
activities-</i>
<br />
<i>-CF: Development progress with two compounds in orphan disease of
cystic fibrosis; combination trial planned with VX-770 and VX-809 based
on Phase 2 data for VX-809-</i>
<br />
<i>-Pipeline: Proof-of-concept clinical trials planned for 2010 with
novel combination regimens for hepatitis C and cystic fibrosis and with
compounds for rheumatoid arthritis and epilepsy-</i>
<br />
<i>-Financial: Vertex enters 2010 with approximately $1.3 billion in
cash, cash equivalents and marketable securities and approximately $32
million in outstanding 2013 convertible debt; 2010 investment to support
long-term business objectives-</i>
<br />
<i>-VX-809 was well-tolerated at all dose levels when dosed once daily
for 28 days-</i>
<br />
<i>-Statistically significant changes observed in measurement of sweat
chloride suggest increased CFTR activity-</i>
<br />
<i>-Data support planned combination trial of VX-809 and VX-770 in
second half of 2010 for CF patients with the F508del mutation-</i>
<br />
<i>-HCV:</i><i>New Drug Application planned for telaprevir in second
half of 2010, robust commercialization and launch preparedness
activities ongoing-</i><br /><i>-CF:</i><i>Advancing development efforts in orphan disease of cystic
fibrosis; Phase 3 STRIVE trial with VX-770 completes planned enrollment,
VX-809 Phase 2 data expected in first quarter 2010-</i><br /><i>-Pipeline:</i><i>Proof-of-concept clinical trials planned for 2010
with novel combination regimens for hepatitis C and cystic fibrosis and
with compounds for rheumatoid arthritis and epilepsy-</i><br /><i>-Financial:</i><i>Vertex enters 2010 with approximately $1.3 billion
in cash, cash equivalents & marketable securities and approximately $32
million in outstanding convertible debt-</i><br />
CAMBRIDGE, Mass., Dec 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Officer. Ms. Wysenski has more than 30 years of experience in building commercial operations and
CAMBRIDGE, Mass., Dec 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per
CAMBRIDGE, Mass., Dec 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering under an effective shelf registration
CAMBRIDGE, Mass., Nov 20, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m.
CAMBRIDGE, Mass., Nov 12, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:40 p.m. EST.
CAMBRIDGE, Mass., Nov 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued
<ul><li class="bwlistitemmarginbottom"><i><b>83% SVR achieved with twice-daily regimen of telaprevir dosed
with PEGASYS and ribavirin</b></i></li><li class="bwlistitemmarginbottom"><i><b>Results highlight the use of response-guided therapy in managing
treatment outcomes</b></i></li><li class="bwlistitemmarginbottom"><i><b>Similar safety and tolerability observed between
telaprevir-based regimens dosed either twice daily or three times daily</b></i></li></ul>
CAMBRIDGE, Mass., Oct 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Oppenheimer 20 th Annual Healthcare Conference on Wednesday, November 4, 2009 at 2:10 p.m.
<ul><li class="bwlistitemmarginbottom"><i><b>57% of prior treatment null responder patients achieved an SVR
with a 48-week telaprevir-based regimen</b></i></li><li class="bwlistitemmarginbottom"><i><b>90% of prior treatment relapsers and 55% of prior treatment
partial responders achieved an SVR with 24-week or 48-week
telaprevir-based regimens</b></i></li><li class="bwlistitemmarginbottom"><i><b>Results provide further support for the ongoing Phase 3
registration study, REALIZE, in treatment-failure patients</b></i></li></ul>
<i>-Phase 3 registration programs in hepatitis C and cystic fibrosis on
track-</i><br /><i>-Vertex to present telaprevir SVR data from Study C208 at AASLD
meeting this week-</i><br />
CAMBRIDGE, Mass., Oct 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2009 financial results on Monday, October 26, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
<i>-Vertex announces plans to initiate a Phase 2 proof-of-concept trial
for VX-509 in rheumatoid arthritis-</i><br /><i>-Vertex to add $260 million to cash position; company increases
guidance for year-end cash position to approximately $800 million and
adjusts net loss guidance-</i><br /><i>-Vertex announces executive leadership change-</i><br />
CAMBRIDGE, Mass., Sep 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes
<i><b>Presentations to include SVR results from Study C208 exploring
twice-daily telaprevir-based dosing regimen, final PROVE 3 results and
additional sub-analysis of PROVE 1 and PROVE 2 in "difficult-to-cure"
patients</b></i><br />
<i>-More than 800 Vertex employees take part in service activities at
more than 20 nonprofit and community organizations around the globe-</i><br /><i>-Several events focused on promoting students' interest in science-</i><br /><i>-Day of Service held to honor Vertex founder and long-time CEO Joshua
Boger, Ph.D.-</i><br />
CAMBRIDGE, Mass., Sep 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 2:30 p.m. EDT and at the JMP Securities Healthcare Conference on
CAMBRIDGE, Mass., Sep 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Thomas Weisel Partners 2009 Healthcare Conference on Wednesday, September 9, 2009 at 2:40 p.m.
CAMBRIDGE, Mass., Aug 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009 at 10:30 a.m. EDT.
<i>- Telaprevir Phase 3 registration program in hepatitis C on track;
NDA submission anticipated in second half of 2010 -</i><br /><i>- Vertex advancing two drug candidates aimed at the underlying
disease mechanism of the orphan disorder cystic fibrosis -</i><br /><i>- Vertex ends second quarter with $754 million of cash, cash
equivalents and marketable securities; Vertex will add to this position
with $105 million of cash through an amended agreement with Mitsubishi
Tanabe Pharma Corporation -</i><br />
<i>-- Vertex to receive $105 million from Mitsubishi following signing,
plus the potential for additional milestones upon commercialization --</i><i>-- Phase 3 registration program for telaprevir in Japan expected to
complete enrollment in the third quarter of 2009 --</i>
CAMBRIDGE, Mass., Jul 27, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2009 financial results on Wednesday, August 5, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
CAMBRIDGE, Mass., Jul 07, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors. "Jeff and Dennis add tremendous medical and biomedical business perspective to our board.
